Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.
暂无分享,去创建一个
R. Gopaul | W. Jefferies | M. David | K. Omilusik | Robyn P. Seipp | A. Setiadi | Kyung-Bok Choi | R. Seipp | Jennifer A Hartikainen | Kyung‐Bok Choi
[1] Wilfred A. Jefferies,et al. Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas , 2007, Molecular and Cellular Biology.
[2] W. Jefferies,et al. TAP expression reduces IL‐10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma , 2007, International journal of cancer.
[3] Jae-Hyung Lee,et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway , 2006, Experimental & Molecular Medicine.
[4] D. Sugarbaker,et al. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. , 2006, The Annals of thoracic surgery.
[5] R. Tampé,et al. Modulation of the antigen transport machinery TAP by friends and enemies , 2006, FEBS letters.
[6] B. Seliger,et al. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. , 2005, Cancer research.
[7] W. Jefferies,et al. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. , 2005, Cancer research.
[8] A. Lund,et al. Epigenetics and cancer. , 2004, Genes & development.
[9] J. Herman,et al. Epigenetic regulation of protein phosphatase 2A (PP2A), Lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells , 2004, Cancer biology & therapy.
[10] M. Maio,et al. Epigenetic targets for immune intervention in human malignancies , 2003, Oncogene.
[11] S. Ferrone,et al. A Single-nucleotide Deletion Leads to Rapid Degradation ofTAP-1 mRNA in a Melanoma Cell Line* , 2003, The Journal of Biological Chemistry.
[12] V. Vonka,et al. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. , 2003, Vaccine.
[13] Victor V Lobanenkov,et al. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. , 2002, Seminars in cancer biology.
[14] S. Berger,et al. Histone modifications in transcriptional regulation. , 2002, Current opinion in genetics & development.
[15] A. Giaccia,et al. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. , 2002, Cancer cell.
[16] R. Tampé,et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. , 2001, Cancer research.
[17] V. Richon,et al. Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.
[18] T. Timme,et al. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. , 2000, Cancer research.
[19] D. Singal,et al. Molecular basis for lack of expression of HLA class I antigens in human small‐cell lung carcinoma cell lines , 1996, International journal of cancer.
[20] Robert Tampé,et al. The transporter associated with antigen processing: function and implications in human diseases. , 2002, Physiological reviews.